Stock WBIO WPD PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Market Closed - Canadian Securities Exchange
Other stock markets
 12:18:01 29/06/2024 am IST 		5-day change 1st Jan Change
0.015 CAD -.--% Intraday chart for WPD Pharmaceuticals Inc. -.--% -66.67%
29/05 WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
08/05 WPD Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
WPD Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline
WPD Pharmaceuticals Inc. Announces Directorate Appointments
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
WPD Pharmaceuticals Inc. Signs Consortium Agreement on EuroNanoMed Project
WPD Pharmaceuticals Inc. Announces Appointment of Romuald Harwas as a Director
WPD Pharmaceuticals Inc. Secures Berubicin Sub-License Rights in Perpetuity
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
WPD Pharmaceuticals Inc.: WPD Pharmaceuticals gibt die Ergebnisse der Jahreshauptversammlung und außerordentlichen Versammlung bekannt
WPD Pharmaceuticals Inc.: WPD Pharmaceuticals gibt die Ergebnisse der Jahreshauptversammlung und außerordentlichen Versammlung bekannt
WPD Pharmaceuticals Inc.: WPD -2-
WPD Pharmaceuticals Inc.: WPD Pharmaceuticals kündigt für den 29. September Hauptversammlung an; plant anderen Weg zur Kapitalbeschaffung durch Delisting; WPD Polen arrangiert zusätzliche Kredite; Kommunikationsberater in Polen
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WBIO Stock
  4. News WPD Pharmaceuticals Inc.
  5. Other languages